Isha Gupta, MD
Ophthalmology · Ogden, UTNPI 1972980332
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,790 of the $11,440 with a category attached, or 85.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,632 and has fallen 82.0% since, to $834 in 2025. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $55.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- NEW World Medical,inc.$2K
- Sight Sciences, Inc.$1K
- AbbVie$1K
- Glaukos Corporation$802
- Aerie Pharmaceuticals, Inc.$732
- plus $3K from 22 others
What the payments were for
- Consulting fees$6506%
- Speaking & faculty fees$1,0009%
- Food & beverage$9,79086%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 39 | $2,484 |
| NEW World Medical,inc. | 12 | $2,186 |
| Sight Sciences, Inc. | 13 | $1,295 |
| AbbVie(2 entities) | 33 | $1,025 |
| Glaukos Corporation | 26 | $802 |
| Aerie Pharmaceuticals, Inc. | 14 | $732 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $565 |
| Bausch & Lomb Americas Inc. | 12 | $297 |
| Ivantis, Inc | 3 | $281 |
| Alimera Sciences, Inc. | 2 | $222 |
| Akorn Operating Company LLC | 11 | $161 |
| Eyevance Pharmaceuticals LLC | 2 | $142 |
| Rxsight Inc | 1 | $142 |
| Kala Pharmaceuticals, Inc. | 2 | $136 |
| Regeneron Healthcare Solutions, Inc. | 2 | $135 |
| Iridex Corporation | 1 | $129 |
| Mallinckrodt Enterprises LLC | 1 | $123 |
| Genentech USA, Inc. | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $90 |
| Sun Pharmaceutical Industries Inc. | 4 | $79 |
| Thea Pharma Inc. | 3 | $56 |
| Novartis | 3 | $51 |
| Apellis Pharmaceuticals, Inc. | 2 | $47 |
| Dompe US, Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 1 | $31 |
| Akorn, Inc. | 2 | $26 |
| Amgen | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$1,661
- Kahook Dual Blade$1,661
- OMNI(R) SURGICAL SYSTEM (US)$792
- Rhopressa$733
- Rocklatan$733
- Centurion$486
- ReSTOR$268
- AcrySof$265
- Hydrus$263
- XEN GLAUCOMA TREATMENT SYSTEM$227
- Iluvien$222
- STELLARIS$220
- ENVISTA$220
- iStent Trabecular Micro-Bypass System Model iS3$163
- iStent inject W$148
- ACTIVEFOCUS$147
- ORA$147
- LenSx$147
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$142
- OMNI$131
How this compares
$11,440 in reported general payments places this provider in the 90th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 56 | $29,970 |
| Latanoprost | 324 | $4,137 |
| Travoprost | 26 | $4,119 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $3,839 |
| Cyclosporine | 13 | $3,635 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $3,303 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 167 | $3,029 |
| Prednisolone Acetate | 72 | $2,706 |
| Brimonidine Tartrate | 79 | $1,044 |
| Timolol Maleate | 73 | $953 |
| Ketorolac Tromethamine | 13 | $332 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 25 | $324 |
| Acetazolamide ErAcetazolamide | 12 | $262 |
| Dorzolamide Hcl | 13 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $1,025 | $29,97056 claims |
| AlconSimbrinza | $2,484 | $3,83918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Ogden
- Michael WilcoxOgden$6K
- Mark BallifOgden$6K
- Jason RuppOgden$4K
- Brock HansenOgden$4K
- Claron AlldredgeOgden$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.